## Objectives: We measured the levels of the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen (ICTP) and osteocalcin (OC) in the serum of 12 rachitic and 27 healthy Nigerian children, and compared the performance of these relatively new markers of bone metabolism with establ
โฆ LIBER โฆ
Change in levels of the carboxyterminal propeptide of type I procollagen, the carboxyterminal cross-linked telopeptide of type I collagen and osteocalcin in response to exercise in well-trained men and women
โ Scribed by H. Salvesen; K. Piehl-Aulin; S. Ljunghall
- Book ID
- 111265168
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 463 KB
- Volume
- 4
- Category
- Article
- ISSN
- 0905-7188
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Serum levels of the pyridinoline crossli
โ
John K. Scariano; Elizabeth A. Walter; Robert H. Glew; Bruce W. Hollis; Allison
๐
Article
๐
1995
๐
Elsevier Science
๐
English
โ 544 KB
Plasma levels of carboxy terminal propep
โ
T Kikuchi; N Hashimoto; T Kawasaki; S Kataoka; H Takahashi; M Uchiyama
๐
Article
๐
2007
๐
John Wiley and Sons
๐
English
โ 91 KB
Serum levels of carboxyterminal propepti
โ
T. Kubo; H. Tanaka; M. Inoue; S. Kanzaki; Y. Seino
๐
Article
๐
1995
๐
Elsevier Science
๐
English
โ 530 KB
The efficacy of the bone markers osteoca
โ
Lars F.H. Theyse; Jan A. Mol; George Voorhout; Maarten Terlou; Herman A.W. Hazew
๐
Article
๐
2006
๐
Elsevier Science
๐
English
โ 184 KB
Bone mineral density and serum levels of
โ
A.K Chandani; J.K Scariano; R.H Glew; J.D Clemens; P.J Garry; R.N Baumgartner
๐
Article
๐
2000
๐
Elsevier Science
๐
English
โ 66 KB
Use of bone turnover marker, pyridinolin
โ
Koga, Hirofumi; Naito, Seiji; Koto, Shuji; Sakamoto, Naotaka; Nakashima, Michita
๐
Article
๐
1999
๐
John Wiley and Sons
๐
English
โ 202 KB
๐ 2 views
BACKGROUND. We investigated whether a new marker of bone turnover, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), could be useful in the assessment of bone metastasis and in monitoring of the response to treatment in patients with prostate cancer with bone metastasi